What the FDA labels say about taking them together
Quinidine and voriconazole
Voriconazole's FDA label of February 26, 2026 names quinidine in its drug interactions section; the quinidine label PlainMeds reads does not name voriconazole. The voriconazole label: “Contraindicated because of potential for QT prolongation and rare occurrence of torsade de pointes.”
Check it at the source: the quinidine FDA label on DailyMed (effective February 1, 2018, Sun Pharmaceutical Industries, Inc.); the voriconazole FDA label on DailyMed (effective February 26, 2026, Roerig).
What does the quinidine label say about voriconazole?
Quinidine's label (effective February 1, 2018) does not name voriconazole in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Quinidine Gluconate), Sun Pharmaceutical Industries, Inc., effective February 1, 2018 (SPL set 5023f053-fcc4-4c2c-aa59-9ec198ad185e), via openFDA; the full label on DailyMed
What does the voriconazole label say about quinidine?
Voriconazole label, drug interactionsDrug/Drug Class (Mechanism of Interaction by Voriconazole): Pimozide, Quinidine, Ivabradine (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased; Prevention or Management Recommendations: Contraindicated because of potential for QT prolongation and rare occurrence of torsade de pointes.
Voriconazole label (Xellia Pharmaceuticals USA LLC, January 11, 2023), contraindicationsCoadministration of pimozide, quinidine or ivabradine with Voriconazole for injection is contraindicated because increased plasma concentrations of these drugs can lead to QT prolongation and rare occurrences of torsade de pointes [see Drug Interactions (7) ].
Voriconazole label (Xellia Pharmaceuticals USA LLC, January 11, 2023), drug interactionsDrug/Drug Class (Mechanism of Interaction by Voriconazole): Pimozide, Quinidine, Ivabradine (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased; Recommendations for Drug Dosage Adjustment/Comments: Contraindicated because of potential for QT prolongation and rare occurrence of torsade de pointes
Source: FDA drug label (Voriconazole, NDA208562), Xellia Pharmaceuticals USA LLC, effective January 11, 2023 (SPL set 9ec6eda2-2f15-423b-9ec6-819379a426e1), via openFDA
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Quinidine | Voriconazole | |
|---|---|---|
| Labeled for | Atrial fibrillation | Fungal infections |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $4.92 per tablet 324 mg tablet | $1.88 per tablet 200 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once